Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration

NCT01500915 is registered in ClinicalTrials.gov with Institut de la Macula y la Retina as lead sponsor.

NCT NCT01500915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration
Lead sponsor
Institut de la Macula y la Retina
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2010
Completion date
July 31, 2012
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

exudative age-related macular degeneration